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ABSTRACT 
Purpose:  Despite effective therapies and treatments, breast cancer survivors often suffer from 
distressing side effects which may increase depressive symptomatology.   Aromatase inhibitors 
(AI) are widely used as adjuvant treatment in breast cancer patients, but are associated with 
side effects such as joint pain that may impact quality of life.  We conducted, in 121 breast 
cancer survivors receiving an AI, a yearlong randomized trial of exercise versus usual care on 
depressive symptomology.   
Methods:  Eligibility criteria included taking an AI for at least 6 months, reporting < 90 minutes 
per week of exercise and no strength training, and reporting > 3 on a scale of 10 for worst joint 
pain on the Brief Pain Inventory (BPI).  Participants were randomly assigned to exercise (150 
minutes per week of aerobic exercise and supervised strength training twice per week) or usual 
care.  The Centers for Epidemiological Studies: Depression Scale (CES-D) was completed at 
baseline and 6- and 12 months.  Intervention effects were evaluated using generalized linear 
models, comparing change at 6- and 12 months.   
Results: Over 12 months, a 4.7 point (36%) decline in CES-D score was seen for women 
randomly assigned to exercise (n = 60) versus a 0.3-point (2%) decline among those receiving 
usual care (n = 60; p <0.05). In secondary analysis, women that scored above the generally 
accepted CES-D score cutoff of 16 (indicating depressive symptomatology), had a 12.6 (+2.6) 
point (50%) decrease (mean+SD) in CES-D score, significantly greater than those in this 
category who were assigned to usual care, 5.5 (+2.8) point decrease (29%).  Women with later 
stage breast cancer, those who had taken AIs for a longer period of time, and those who had 
attended more supervised exercise sessions showed a greater decrease in CES-D scores 
compared to their counterparts.   
Conclusion:  Exercise led to favorably reductions in CES-D scores in previously inactive breast 
cancer survivors taking AIs.  Exercise programs should be implemented for breast cancer 
survivors in an effort to reduce depressive symptoms.   
4 
 
Table of Contents 
 
Introduction   5 
 
Methods   6 
 
Results    10 
 
Discussion    13 
 
References    16 
 
Figure 1   18 
 
Tables    19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
INTRODUCTION 
There are approximately 3.1 million breast cancer survivors in the United States, a result 
in part of improved treatments.1 With survival rates increasing, researchers are increasingly 
looking at side effects that affect quality of life in breast cancer survivors.  Cancer survival can 
be accompanied by adverse physiological and psychological side effects, such as weight 
changes, decreased strength and flexibility, and depression and anxiety. 2-6 
 Depression is a relatively common side effect of cancer and cancer treatment and its 
prevalence varies by cancer site.7 Depression is characterized by feelings of sadness, 
hopelessness, changes in sleep and appetite, psychomotor retardation, and withdrawal from 
social contact.7 Cancer survivors may experience fear of death, disease relapse, and body 
image changes that can contribute to a reduced quality of life and impaired social and 
occupational functioning.  Depression in cancer survivors is often correlated to various 
comorbities, such as obesity, diabetes, and the development of cardiovascular disease.8   
Breast cancer survivors are at an increased risk for depression, due to the side effects of 
cancer treatment.  The prevalence of depression among breast cancer survivors ranges widely 
from 1.5 to 46 percent, dependent on variables such as age, treatment, number of children at 
home, and socioeconomic status .9 Current treatments for depression in cancer survivors 
include pharmacologic interventions and psychotherapy.  For many, these treatments are safe, 
effective, and provide significant benefit.  For others, they may have limited usefulness because 
of personal, behavioral, or biological factors.7  
 Additionally, other breast cancer treatment-related side effects may increase depression 
symptomatology.  Agents such as steroids and estrogen depleting interventions, which can alter 
serotonin levels, are associated with the development of depression.10 Aromatase inhibitors (AI) 
are widely used as adjuvant treatment for postmenopausal women with estrogen receptor-
positive breast cancer and act through estrogen depletion.  Arthralgia (i.e., joint pain) is one of 
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the major complaints of breast cancer patients undergoing AI treatment, and may be associated 
with worse overall quality of life and psychological well-being.11  
Exercise has been identified as a treatment that may provide symptom relief for 
depression, as well as improve physical health outcomes in cancer survivors.12 Accumulating 
evidence suggests exercise after diagnosis of cancer may improve functional capacity, 
muscular strength, and reduce cancer-related fatigue.  Trials of exercise among breast cancer 
survivors have generally had small sample sizes and have varied widely in quality and in 
specifics such as exercise prescription, time since diagnosis, and choice of patient-reported 
outcomes.  Recent systematic reviews and meta-analyses have reported clear benefits of 
physical activity for cardiovascular fitness in breast cancer survivors, but report only generally 
modest or inconsistent effects for outcomes like depression.13 No large-scale randomized 
controlled trial assessing the effect of exercise on depression in breast cancer survivors, in 
particular, those taking AIs, has been conducted.   
 We recently completed a randomized trial, the Hormones and Physical Exercise (HOPE) 
Study, which examined the effect of an exercise intervention vs. usual care on AI side-effects in 
breast cancer survivors.  The purpose of this paper was to evaluate how the HOPE exercise 
intervention vs. usual care impacted depression scores in women taking AIs and experiencing 
arthralgia.   
METHODS   
 The HOPE Study was a yearlong, randomized control trial, which evaluated the effect of 
an exercise intervention vs. usual care (control) on AI side-effects.  All study procedures, 
including written informed consent, were approved by the Yale School of Medicine Human 
Investigation Committee and Connecticut Department of Public Health and Human Investigation 
Committee.   
 
 
7 
Study Participants and Recruitment 
 Breast cancer survivors were recruited between June 1, 2010 and December 30, 2012 
from 5 hospitals in Connecticut through the Rapid Case Ascertainment Shared Resource of the 
Yale Cancer Center (RCA), a field arm of the CT Tumor Registry.  Detailed recruitment methods 
are described elsewhere.14 
 Eligible participants were physically inactive (<90 min/wk of physical activity in the past 
six months and no strength training in the past year), postmenopausal women, diagnosed 0.5-
4.0 years prior to enrollment with hormone receptor positive Stage I to III breast cancer, who 
had taken an AI for at least six months prior to enrollment.  Participants had to be experiencing 
arthralgia for at least two months prior to enrollment that was a minimum of mild in severity, 
defined as a score of at least 3 out of 10 on the worst pain item of the Brief Pain Inventory.15 
Women were eligible if arthralgia started after initiation of an AI or if they had pre-existing join 
pain as long as the pain or stiffness was exacerbated by AI use. 
Primary Outcome Measures 
Depression: Depression was assessed with the Centers for Epidemiological Studies – 
Depression Scale16 (CES-D). The CES-D is a 20-item scale designed to measure current level 
of depressive symptomatology, with emphasis on the affective component, depressed mood.  
The 20 items are divided into four domains: Somatic Retarded Activity (7 items), Depressed 
Affect (5 items), Positive Affect (4 items), and Interpersonal Affect (2 items), and 2 single items 
that complete the total score.17  The possible range of scores is zero to 60, with higher scores 
indicating more symptoms, weighted by frequency of occurrence during the past week.16 The 
construct validity and internal consistency of the CES-D are good.17  The positive predictive 
value is 54.5% for the cut-off score of 16 in head and neck cancer patients,17 which was also 
used as the cutoff score for this population.  A group with a high average score may be 
interpreted to be “at risk” of depression or in need of treatment.  The scale is a valuable tool to 
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identify such high-risk groups and the relationships between depressive symptoms and other 
variables.  
Secondary Outcome Measures and Covariate Measures 
An interviewer-administered questionnaire at the baseline visit was used to assess 
disease stage, type of surgery, adjuvant therapy, and comorbidities.  Stage was self-reported, 
and was subsequently verified using medical records.  Additionally, we collected information on 
participants’ race/ethnicity, education level, time since diagnosis, time on AI, and height and 
weight.  Height and weight were measured at baseline, 6-, and 12 months.  Participants were 
weighed on a digital scale in light clothing, without shoes.  Height without shoes was measured 
using a stadiometer.  All measurements were taken twice and averaged.  Exerciser trainers 
were responsible for recording attendance to the supervised exercise training sessions.  
Physical activity was recorded at baseline, 6-, and 12 months, via an interviewer-administered 
physical activity questionnaire, assessing the past 6 months of recreational activity including the 
type, frequency, and duration of 20 activities.18 
Exercise Intervention  
 To comply with current exercise recommendations for cancer survivors,19 the yearlong 
exercise intervention was a combination of a twice-weekly supervised exercise training program 
consisting of resistance and aerobic exercise (under supervision of an American College of 
Sports Medicine certified cancer exercise trainer) at a local health club and additional aerobic 
exercise on their own (at home or the gym), for a total of 150 min/wk of aerobic exercise.  
Detailed information about the intervention protocol has been previously reported.14  Following 
each exercise session, participants recorded the type of duration, and average heart rate during 
exercise, in physical activity logs.20  Participants returned logs to the exercise trainers at the end 
of each week.  Exercise trainers also recorded attendance to the supervised exercise session.   
 The aerobic exercise intervention consisted primarily of brisk walking, either on a 
treadmill or outside, although participants were allowed to choose other aerobic exercise 
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training, such as stationary bicycling or using the elliptical machine.  Exercise started at 50% of 
maximal heart rate (determined from VO2 max testing) and gradually increased over the first 
month to 60-80% of maximal heart rate for the duration of the study.  The strength training 
protocol consisted of six exercise: bench press, latissimus pull down, seated row, leg press, leg 
extension, and leg curl.  Each of these exercises were performed for 8-12 repetitions for three 
sets.  A standard progressive resistance training approach was used in which participants 
progressed up to three sets per exercise over the first month of training.  After two sessions 
during which a participant lifted the same weight 12 times during each set, the weight was then 
increased by the smallest possible increment.   
Usual Care Group 
 Women were instructed to continue with their usual activities.  Participants were not 
discouraged from exercise on their own but were not given any exercise instruction.  Both the 
exercise and usual care groups were provided with an educational booklet prepared for the 
HOPE study, which addressed breast cancer topics such as lymphedema and fatigue.  These 
topics were discussed monthly over the phone for the usual care group, or at an exercise 
session for the exercisers.  Participants in this group were called monthly by research staff to 
determine AI adherence.  In addition, AI adherence was assessed in the usual care group at the 
monthly phone call.  At the completion of 12 months, women were offered a supervised exercise 
session and exercise handouts.   
Statistical Analyses 
 Descriptive statistics were used to describe the study population based on socio-
demographic and clinically relevant indicators according to study randomization.  Participants 
were analyzed using the intention-to-treat principle.  For those women who did not have six-
month questionnaires, the change in CES-D was imputed as 0.  Generalized linear models 
(GLM) were used comparing women randomized to the exercise intervention arm and women 
randomized to the usual care group on depressive symptomatology.  Potential covariates 
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included baseline CES-D score, cancer stage, age, time since diagnosis, and time on AI.  Only 
14 women reported previous diagnosis of depression, and 11 of those women reported taking 
antidepressants at baseline.  Because of the small number, the effect was assumed to be very 
small and this was not included in analysis.  In looking at attendance using the average minutes 
per week, a t-test was performed to analyze if changes were significant from baseline. 
Owing to the relatively low CES-D score observed at baseline, secondary analyses were 
conducted to determine the effect of exercise on CES-D by the baseline CES-D cutoff of 16.  
We also examined effect modification by disease stage and time on AI.  Analysis was performed 
using SAS version 9.3 (Cary, NC).  Statistical significance was set at p<0.05 using 2-sided 
tests.   
RESULTS 
 A total of 1,537 breast cancer survivors were identified through the Rapid Case 
Ascertainment (RCA) Shared Resource of the Yale Cancer Center (Figure 1).  Screening phone 
calls were completed with 1016 women.  Of these 1016 women screened, 253 women had 
already stopped taking an AI because of side effects or chose not to take and AI because of 
potential side effects.  A total of 121 women were randomized.  One woman did not complete 
the baseline CES-D, and was subsequently removed from statistical analysis resulting in an 
analytic sample of 120.  Given funding cuts, the last 25 of the 121 women recruited were 
enrolled into a 6-month rather than a 12-month trial.  Thus, their study adherence and attrition is 
based on 6-month data.  Study attrition was low, with 58 of 61 exercisers (95%) and 49 of 60 
usual care women (82%) completing 6-month measures, and 45 of 48 exercisers (94%) and 39 
of 48 usual care women (81%) completing 12-month measures.   
 Women randomly assigned to exercise reported their exercise prospectively in daily 
activity logs and reported and average 119 minutes per week of exercise, with an average of 
70% of strength training sessions completed.  There were no adverse events associated with 
the exercise program. 14 
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Baseline Characteristics 
 The average age of participants was 61 years (Table 1).  The majority of the study 
population were white (88%) and diagnosed with Stage I breast cancer (59%).  A large portion 
of the study participants had a lumpectomy or partial mastectomy (65%) and had an average 
time between diagnosis and enrollment of 2.0 years. All baseline characteristics were similar for 
both arms (p > 0.05).   
Effect of Exercise on CES-D 
 At baseline, CES-D scores were similar in both groups (12.3+1.3 exercise group and 
12.5+1.3 usual care; p = 0.89) (Table 2). Thirty-five individuals (29%) scored a 16 or greater on 
the CES-D, indicating a higher level of depressive symptomatology.  At the 6-month follow-up, 
CES-D scores decreased by 3.5 (+0.8) points (28%) in women randomized to exercise 
compared to a 0.6 (+0.8) decrease (5%) in women randomized to usual care (difference = 2.9; p 
= 0.018) Table 2.  Adjustment for age, time since diagnosis, time on AI, race, education, stage, 
surgery, treatment, BMI, BPI, and baseline CES-D scores did not affect the results (results not 
shown). 
 Stratified analyses examining the effect of the intervention specifically within those 
participants who reported CES-D >16 scores at baseline.  At baseline, 18 study participants 
(15%) randomized to the exercise arm and 17 study participants (14%) randomized to the usual 
care group scored at or above the generally accepted cutoff of 16, suggesting a potentially 
elevated rate of depressive symptoms.   In looking at those who scored at or above 16 on the 
baseline CES-D, participants baseline CES-D score averaged 23.7 + 7.9 and 26.8 + 8.8 for 
exercisers and usual care, respectively (p = 0.272) (Table 3).  At 6 months, CES-D scores 
decreased 12.06 (+2.0)  points (48%) in women randomized to exercise verse 5.23 (+2.1) points 
(22%) in women randomized to usual care (difference = 6.83 p=0.025). 
 Similar findings were observed when measuring mean difference of CES-D scores in 
comparison to stage of breast cancer at diagnosis.  Individuals diagnosed with stage 0 and I 
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had averaged baseline CESD scores of 11.4 + 8.8 and 12.9 + 11.6 for exercisers and usual 
care (p=0.39) (Table 4).  Those diagnosed with later stage II or III breast cancer had averaged 
baseline CESD scores of 14.9 + 11.3 and 13.6 + 9.6 (p =0.40).  At 12 months, the CES-D 
change among those in the exercise intervention at both earlier and later stages was 
significantly greater than those in the usual care group.  Furthermore, for those with later stage 
breast cancer, their depressive symptom scores decreased by 6.0 points compared to those of 
the same stage randomized to usual care group, whose scores increased by 1.7 (difference = 
7.7; p = 0.006).   
 Baseline CES-D scores were comparable for participants taking an AI for less than 20 
months and greater than 20 months (p = 0.781 and p = 0.558) (Table 4).  Significant decreases 
in CES-D scores can be seen in those have been on an AI for a longer period of time.  Over 12 
months, CES-D scores decreased by 5.1(+1.1) points in women randomly assigned to exercise, 
versus a 2.2 (+1.2) increase in women randomly assigned to usual care (difference = 7.3; p = 
<0.001).  Adjusting for age, stage, race, surgery, treatment, and BMI did not affect the results.  
Attendance was examined by using the median of 82 minutes per week.  Twenty-nine women 
averaged more than 82 minutes per week, decreased their CES-D score by 6.2 (+1.3) at 12 
months, compared to the 31 women who averaged less than 82 minutes per week and loss 
approximately 3.4 (+1.4) points.  CES-D scores in both high and low attendance groups 
decreased significantly compared to baseline (p=<0.001) (Table4).  Similarly, significant 
decreases in CES-D scores over time were seen for both attendance groups at the 6-month 
time point. 
DISCUSSION 
 In this exercise intervention trial in women receiving AI therapy for breast cancer, we 
found depressive symptomatology decreased significantly more in those in the exercise 
intervention versus usual care.  Baseline scores were comparable to other published research 
looking at the quality of life, using the CES-D in breast cancer survivors,9 21 22 On average, 
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depression scores in women randomly assigned to exercise decreased from moderate at 
baseline to mild at the end of the intervention period (ie, CES-D score of approximately 
moderate score of 12 to mild score of 7).  To our knowledge, this is the strongest 
methodological study, given the randomized design, large sample size, and 12-month 
intervention period, that has examined the effect of exercise on depression in breast cancer 
survivors on AI therapy.   
 The largest effects of depression changes in cancer survivors have been found in those 
who participated in programs in which all or majority of the exercise was supervised, as 
compared with those exercising in the home.7 This suggests caution in how exercise programs 
are implemented for breast cancer survivors if reduction in depression is a goal.  The majority of 
exercise interventions designed for cancer survivors, including HOPE, are not likely designed to 
target depressive symptoms.  Research has shown that duration of exercise session was not a 
significant moderator of the effect of exercise on depression,7 but frequency of exercise was an 
important factor, an exercise frequency of 5 times per week was reported as being significantly 
more effective than 2 to 4 days of activity.23 Future research could compare the effect of a 
variety of exercise intensities and varying lengths of exercise sessions on depression so that 
evidence based recommendations can be made about the appropriate exercise prescription for 
breast cancer survivors with regard to reducing depression.  
Our study has some limitations.  Participants in the HOPE study were primarily non-
Hispanic white, well educated, and diagnosed with Stage I breast cancer; therefore do not 
constitute a representative sample of the overall population of breast cancer survivors. Women 
with breast cancer who have lower socioeconomic status (SES) have an increased risk of 
developing depression; with symptom burden differing by race and SES.24  Ideally future studies 
will include larger numbers of breast cancer patients from ethnic minorities and those who have 
low SES; giving a clearer view of potential moderator variables.  Additionally, although most of 
the participants were recruited from tumor registries, given the sizable time commitment, it is 
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very possible that those women who elected to enroll in the study were higher functioning than 
breast cancer survivors, in general.  Most participants in HOPE scored within a “normal” range 
on the CES-D, lower than a score of 16.  In observing a significantly greater decrease in 
depressive symptomatology among those in the exercise arm, future studies could use 
depression symptomatology as an entry criterion. 
 Strengths of the HOPE study include the randomized design, high adherence to 
exercise, and a focus on women experiencing arthralgia resulting from AI use. Studies looking 
into AI-induced arthralgia are mostly small (<59 participants), uncontrolled, and of short 
duration.14 However, depression was not the primary outcome of the HOPE trial and as a result 
limited information was collected about the participant’s history of depression, ongoing 
treatment for depression, length of current depressive symptoms, or additional psychologic 
comorbities.  With more specific information about onset, persistence, and treatment for specific 
depression bouts, potential moderators could be examined in more detail.   
 Furthermore, a final strength of this study was a focus on a sample of women at higher 
risk for depression because of treatment side effects.  AIs are often well tolerated with very few 
serious adverse events, but common side effects include joint pain, loss of bone mineral 
density, hot flashes, night sweats, and vaginal dryness.25  These side effects are the primary 
cause of discontinuation and often responsible for exacerbating depressive feelings and could 
be a reason for higher baseline CES-D scores.  Women in the HOPE study had reported the 
side effect of arthralgia prior to enrollment.  Improvement in arthralgia potentially stands as a 
potential mediator of improving depression or vice versa.  For instance, exercise was shown to 
improve depressive symptomatology, which may in turn improve the side effect of joint pain, or 
the psychological factors associated with pain.  Appropriate management of AI side effects is of 
critical importance for overall quality of life and to ensure adherence. 
 In conclusion, the HOPE exercise intervention improved depressive symptomatology as 
measured by the CES-D.   However, further research is necessary using a more diverse 
15 
population and targeting at risk populations.  With more women surviving breast cancer, it 
becomes important to understand their experiences in survivorship and to give clinicians 
treating them realistic expectations about the prevalence of psychological difficulties.   
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 Fig 1. Flow of participants through Hormones and Physical Exercise study. 
 
 
Cases ascertained from 
tumor registry 
N = 1537 
Physician consent given and recruitment letter mailed to participant 
telling them we will call within 1 week to screen 
(n = 1,393) 
No physician consent 
N = 144 
 
Consent decline (n = 130) 
No response (n = 14) 
Screened via telephone 
(n = 1,016) 
Unable to contact/screen 
(n=412) 
Disconnected (n = 62) 
Wrong number (n = 41)  
No answer (n = 26) 
Busy signal (n = 3) 
Voice message (n = 280) Call in (non-tumor 
registry case) 
(n = 35) 
Ineligible   (n = 660) 
  Not on AI  (n = 253) 
  No joint pain (BPI<3) (n = 147) 
  Physical illness  (n = 89) 
  Too physically active (n = 86) 
  Lives out of state  (n = 39) 
  Does not speak English (n = 29) 
  Mental illness  (n = 7) 
  No transportation (n = 7) 
  Not feeling well  (n = 3) 
Not interested  (n = 235) 
  Not interested  (n = 95) 
  No time  (n = 77) 
  Unwilling/unable to  (n = 22) 
    participate 
  Lives too far away  (n = 14) 
  Gym too far  (n = 12) 
  Declined/vague reason (n = 9) 
  Hang up   (n = 6) 
Randomly assigned 
(n = 121) 
 
Exercise group (n = 61) 
 
Usual care group (n = 60) 
Completed 6 months (n = 58/61; 
95%) 
Completed 6 months (n = 49/60; 
82%) 
Completed 12 months; (n = 45/48; 
94%) 
Completed 12 months (n = 38/48; 
80%) 
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Table 1. Baseline Characteristics (n=120)a 
 
Characteristic Exercise (n=60)b Usual Care (n=60)b pc 
Age (years)  62.0 + 7.0 60.5 + 7.0 0.245 
Body mass index (kg/m2) 30.0 + 6.8 28.7 + 5.5 0.275 
Time on AI 1.9 + 1.9 1.8 + 1.3 0.888 
Race/Ethnicity (%)   0.846 
Non-Hispanic White 86.9 88.3  
Hispanic 1.6 5.0  
African American 9.8 6.7  
Asian/Pacific Islander 1.6 1.7  
American Indian 0.0 1.67  
Education (%)   0.290 
High school graduate 9.8 15.0  
Some school after high school 32.8 41.7  
College graduate + 57.4 43.3  
Stage (%)   0.909 
Stage 0 (in situ) and Stage I 60.7 61.7  
Stage II and Stage III 39.3 38.3  
Surgery (%)   0.796 
Lumpectomy or partial mastectomy 70.5 65.0  
Unilateral mastectomy 16.4 18.3  
Bilateral mastectomy 13.1 16.7  
Treatment (%)   0.633 
Chemotherapy 6.6 8.33  
Radiation 36.1 40.0  
Chemotherapy and Radiation 45.9 35.0  
Surgery Only 11.5 16.7  
Time Since Diagnosis 2.7 + 3.1  3.3 + 3.9 0.303 
 
 
a Table values are mean + SD for continuous variables and % for categorical values. 
b Percentages may not sum to 100% due to rounding. 
c P-value is for t-test (continuous variables), x2 test (categorical variables), or Fisher’s exact test (cell 
counts < 5).  
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Table 2. Effect of exercise vs. usual care on depression changes at baseline, 6-, and 12 monthsa, b 
 Exercise 
(n=60) 
Usual Care 
(n=60) 
p-value 
Baseline 12.3 (1.3) 12.5 (1.3) 0.885 
6 Month 8.9 (1.1) 11.9 (1.1) 0.054 
Change -3.5 (0.8) -0.6 (0.8) 0.018 
 Exercise 
(n=45) 
Usual Care 
(n=38) 
 
12 Month 7.9 (1.2) 12.5 (1.4) 0.011 
Change -4.7 (1.0) 0.3 (1.1) 0.001 
a Numbers are change in CES-D using least-square mean (SE) 
b Model controls for baseline CES-D score and study arm 
 
 
Table 3. Mean depression scores and changes of those above and below CES-D score of 16 at baseline, 
6-, and 12 months.a 
  Exercise (n=60) Usual Care 
(n=60) 
P-value 
CESD > 16 
(n=35) 
Baseline 23.7 (7.9) 26.8 (8.8) 0.272 
 6 Month 12.3 (7.7) 20.9 (11.2) 0.012 
 Change -12.06 (2.0) -5.23 (2.1) 0.025 
 12 Month  11.9 (9.7) 19.1 (10.3) 0.084 
 Change -12.6 (2.5) -5.5 (2.8) 0.073 
CESD < 16 
(n=85) 
Baseline 7.4 (4.5) 6.9 (4.21) 0.599 
 6 Month 7.4 (5.6) 8.3 (6.6) 0.513 
 Change 0.1 (0.8) 1.3 (0.8) 0.308 
 12 Month  6.1 (5.8) 9.9 (6.4) 0.021 
 Change -1.3 (1.0) 2.9 (1.0) 0.005 
a Numbers are change in CES-D using least-square mean (SE) 
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Table 4: Change in CES-D Stratified by Study Variablesa 
 
 Change in 
CES-D 
Exercise 
Intervention 
LSMEAN (SE) 
Change in 
 CES-D 
Usual  
Care 
LSMEAN (SE) 
 
 
 
p 
Stage O and I (n=75) 
6 month 
12 month 
 
-2.5 (1.1) 
-4.0 (1.1) 
 
-1.2 (1.1) 
-0.2 (1.2) 
 
0.370 
0.027 
Stage II and III (n=45) 
6 month 
12 month 
 
-4.8 (1.4) 
-6.0 (1.8) 
 
0.3 (1.4) 
1.7 (1.9) 
 
0.013 
0.006 
AI < 20 months (n= 59) 
6 month 
12 month 
 
-3.3 (1.2) 
-4.6 (1.7) 
 
0.1 (1.2) 
-1.4 (1.8) 
 
0.054 
0.198 
AI > 20 months (n = 59) 
6 month 
12 month 
 
-4.0 (1.3) 
-5.1 (1.1) 
 
-1.0 (1.2) 
2.2 (1.2) 
 
0.097 
<0.001 
Attendance < 82 (n = 29)b 
Min per week              6 month 
12 month 
 
-3.2 (1.2) 
-3.4 (1.4) 
 
N/A 
N/A 
 
<0.001 
<0.001 
Attendance > 82 (n = 31)b 
Min per week              6 month 
12 month 
 
-4.2 (1.0) 
-6.2 (1.3) 
 
N/A 
N/A 
 
<0.001 
<0.001 
 
a Numbers are change in CES-D using least-square mean (SE) 
b P-value is for t-test  
 
 
